Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective human factor validation study of epinephrine prefilled syringe (Symjepi) for the treatment of acute anaphylaxis.

Next Previous
Trial Profile

Prospective human factor validation study of epinephrine prefilled syringe (Symjepi) for the treatment of acute anaphylaxis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epinephrine (Primary)
  • Indications Anaphylaxis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 13 Mar 2018 New trial record
  • 06 Mar 2018 According to the Adamis Pharmaceuticals Corporation, company provided an update on data presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) joint congress with the World Allergy Organization.
  • 06 Mar 2018 Results presented in the Adamis Pharmaceuticals Corporation media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top